CVGR

Covalent (CVGR)

Covalent

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CVGR

1 2 3 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2006/10/31	01 : 34	Business Wire	Covalent Group Changes Name to Encorium Group, Inc.	NASDAQ:CVGR	Covalent
2006/10/21	05 : 08	Business Wire	Covalent Group, Inc. Announces Results of Shareholder Vote	NASDAQ:CVGR	Covalent
2006/10/19	21 : 01	Business Wire	Covalent Signs $8.2 Million in Contracts For Multinational Studies to Treat Influenza	NASDAQ:CVGR	Covalent
2006/08/09	05 : 36	Business Wire	Covalent Reports 2006 Second Quarter Financial Results; Company to Hold Conference Call at 9:00 AM on Wednesday, August 9, 2006	NASDAQ:CVGR	Covalent
2006/08/07	21 : 24	Business Wire	Covalent Group, Inc. Announces $1.7 Million Contract For Phase 2 Clinical Trial in Atherosclerosis	NASDAQ:CVGR	Covalent
2006/08/02	23 : 14	Business Wire	Covalent Group, Inc. Schedules Second Quarter Financial Results and Conference Call	NASDAQ:CVGR	Covalent
2006/07/14	01 : 00	Business Wire	Covalent Group, Inc. Signs Contracts Totaling $1.5 Million for Clinical Studies Offering Advanced Therapeutic Approaches to Pat	NASDAQ:CVGR	Covalent
2006/07/07	03 : 15	Business Wire	Covalent Group Amends Business Combination Agreement with Remedium Oy	NASDAQ:CVGR	Covalent
2006/06/28	21 : 27	Business Wire	Covalent Group, Inc. Announces $2.1 Million of New Business Contracts; Reiterates Second Quarter Guidance	NASDAQ:CVGR	Covalent
2006/05/16	06 : 22	Business Wire	Covalent Reports 2006 First Quarter Financial Results and Summary Balance Sheet Data; Company to Hold Conference Call at 9:00 A	NASDAQ:CVGR	Covalent
2006/05/08	21 : 12	Business Wire	Covalent Group, Inc. Schedules First Quarter Financial Results and Conference Call	NASDAQ:CVGR	Covalent
2006/04/20	21 : 07	Business Wire	Covalent Group, Inc. Signs $1 Million Contract To Conduct Phase 1 Study of Drug to Prevent/Treat Infectious Disease	NASDAQ:CVGR	Covalent
2006/03/30	22 : 00	Business Wire	Covalent Group, Inc. Announces Additional New Business Contracts	NASDAQ:CVGR	Covalent
2006/03/22	07 : 15	Business Wire	Covalent Group, Inc. Announces $2.1 Million Contract To Conduct Patient Disease Registry In Hospitalized Subjects With Hyponatr	NASDAQ:CVGR	Covalent
2006/03/22	07 : 14	Business Wire	Covalent Group, Inc. Signs $1.3 Million in Consulting and Medical Writing Contracts to Support New Drug Applications (NDA) for	NASDAQ:CVGR	Covalent
2006/03/22	07 : 12	Business Wire	Covalent Reports 2005 Fourth Quarter and Year End Financial Results and Summary Balance Sheet Data; Company to Hold Conference	NASDAQ:CVGR	Covalent
2006/03/16	21 : 57	Business Wire	Covalent Group, Inc. Schedules Fourth Quarter Financial Results and Conference Call	NASDAQ:CVGR	Covalent
2006/03/03	22 : 12	Business Wire	Covalent Group, Inc. Enters into Combination Agreement with Remedium Oy; Conference Call Scheduled for 11:00 AM ET Today	NASDAQ:CVGR	Covalent
2006/02/08	23 : 31	Business Wire	Covalent Group, Inc. and Sudler & Hennessey Announce Strategic Partnership to Design and Conduct Global Patient Disease Registri	NASDAQ:CVGR	Covalent
2006/02/02	22 : 01	Business Wire	Covalent Group, Inc. Signs $2.2 Million Contract With New Sponsor to Conduct Clinical Trial in Patients with Cardiovascular Dise	NASDAQ:CVGR	Covalent
2006/02/01	02 : 00	Business Wire	Covalent Group, Inc. Retains The Equity Group to Provide Investor Relations Services	NASDAQ:CVGR	Covalent
2006/01/24	22 : 00	PR Newswire (US)	Covalent Group, Inc. Announces Multiple New Business Contracts with an Aggregate Value of $1.0 Million	NASDAQ:CVGR	Covalent
2006/01/18	22 : 00	PR Newswire (US)	Covalent Group, Inc. Signs Contract for $2.3 Million to Conduct a Multinational Phase 2 Clinical Trial Involving a New Antithrom	NASDAQ:CVGR	Covalent
2005/12/08	21 : 00	PR Newswire (US)	Covalent Group, Inc. Signs Letter-of-Intent to Conduct $2.2 Million Multinational Phase 2 Clinical Trial in Cardiovascular Disea	NASDAQ:CVGR	Covalent
2005/12/05	21 : 01	PR Newswire (US)	Covalent Group, Inc. and Emergent BioSolutions Sign Contract to Develop Immune Globulins for Treatment Exposure of Anthrax Infec	NASDAQ:CVGR	Covalent
2005/11/18	23 : 30	PR Newswire (US)	CSC's DVC Reaches Milestone in Plague Vaccine Clinical Trial	NASDAQ:CVGR	Covalent
2005/11/12	00 : 20	PR Newswire (US)	/C O R R E C T I O N -- Covalent Group, Inc. /	NASDAQ:CVGR	Covalent
2005/11/11	07 : 01	PR Newswire (US)	Covalent Reports Results for Third Quarter 2005	NASDAQ:CVGR	Covalent
2005/11/07	22 : 03	PR Newswire (US)	Covalent Group, Inc. to Report Third Quarter 2005 Results on Thursday, November 10	NASDAQ:CVGR	Covalent
2005/10/06	22 : 01	PR Newswire (US)	Covalent Group, Inc. Announces $5.3 Million Contract to Provide Additional Services for a Global Phase 3 Trial in Hypertension	NASDAQ:CVGR	Covalent